Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease.

IF 2.1 3区医学 Q2 OPHTHALMOLOGY

Japanese Journal of Ophthalmology Pub Date : 2025-05-16 DOI:10.1007/s10384-025-01199-y

Yoshihiro Nakagawa, Yoshifumi Murayama, Yasuyuki Suzuki, Atsushi Uchiyama, Takahiro Suzuki

{"title":"Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease.","authors":"Yoshihiro Nakagawa, Yoshifumi Murayama, Yasuyuki Suzuki, Atsushi Uchiyama, Takahiro Suzuki","doi":"10.1007/s10384-025-01199-y","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the efficacy of intravitreal injections of ranibizumab (IVR) in treating zone II stage 2 retinopathy of prematurity with plus disease (ROP II2+) in preterm infants, focusing on two primary outcomes: reactivation and persistent avascular retina (PAR).Study design: Retrospective and consecutive case series.Methods: This retrospective study reviewed the medical records of preterm infants treated with IVR at Tokai University hospital between December 2019 and September 2023. Data on reactivation, PAR, and other clinical outcomes were analyzed using generalized estimating equations to account for correlations between eyes.Results: Thirty eyes from 16 infants received IVR treatment. Following initial IVR all eyes achieved remission for over one year with IVR alone. Forty percent of these eyes required subsequent treatment due to reactivation, with a median reactivation time of 70 days. One year after initial IVR, PAR was observed in 11 out of the 30 eyes. Lower birth weight was associated with a tendency toward reactivation, and it also showed a significant correlation with the development of PAR.Conclusions: This research supports the effectiveness of IVR for ROP II2+ over a one-year period. The links between lower birth weight and both reactivation and PAR might guide refinements in therapeutic strategies.","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10384-025-01199-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the efficacy of intravitreal injections of ranibizumab (IVR) in treating zone II stage 2 retinopathy of prematurity with plus disease (ROP II2+) in preterm infants, focusing on two primary outcomes: reactivation and persistent avascular retina (PAR).

Study design: Retrospective and consecutive case series.

Methods: This retrospective study reviewed the medical records of preterm infants treated with IVR at Tokai University hospital between December 2019 and September 2023. Data on reactivation, PAR, and other clinical outcomes were analyzed using generalized estimating equations to account for correlations between eyes.

Results: Thirty eyes from 16 infants received IVR treatment. Following initial IVR all eyes achieved remission for over one year with IVR alone. Forty percent of these eyes required subsequent treatment due to reactivation, with a median reactivation time of 70 days. One year after initial IVR, PAR was observed in 11 out of the 30 eyes. Lower birth weight was associated with a tendency toward reactivation, and it also showed a significant correlation with the development of PAR.

Conclusions: This research supports the effectiveness of IVR for ROP II2+ over a one-year period. The links between lower birth weight and both reactivation and PAR might guide refinements in therapeutic strategies.

查看原文本刊更多论文

雷尼单抗治疗ii区2期早产儿视网膜病变的疗效

目的：本研究旨在评估玻璃体内注射雷尼珠单抗（IVR）治疗早产儿II区2期视网膜病变伴伴疾病（ROP II2+）的疗效，重点关注两个主要结局：再激活和持续性无血管视网膜（PAR）。研究设计：回顾性和连续的病例系列。方法：本回顾性研究回顾了东海大学医院2019年12月至2023年9月期间接受IVR治疗的早产儿的医疗记录。再激活、PAR和其他临床结果的数据使用广义估计方程进行分析，以解释眼睛之间的相关性。结果：16例患儿30只眼接受IVR治疗。以下最初的IVR所有的眼睛达到缓解一年以上的IVR单独。由于再激活，40%的眼睛需要后续治疗，平均再激活时间为70天。术后一年，30只眼中有11只出现PAR。较低的出生体重与重新激活的趋势有关，并且与par的发展也显示出显著的相关性。结论：本研究支持IVR对ROP II2+的有效性，为期一年。低出生体重与再激活和PAR之间的联系可能会指导治疗策略的改进。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Ophthalmology 医学-眼科学

CiteScore

4.80

自引率

8.30%

发文量

审稿时长

6-12 weeks

期刊介绍： The Japanese Journal of Ophthalmology (JJO) was inaugurated in 1957 as a quarterly journal published in English by the Ophthalmology Department of the University of Tokyo, with the aim of disseminating the achievements of Japanese ophthalmologists worldwide. JJO remains the only Japanese ophthalmology journal published in English. In 1997, the Japanese Ophthalmological Society assumed the responsibility for publishing the Japanese Journal of Ophthalmology as its official English-language publication. Currently the journal is published bimonthly and accepts papers from authors worldwide. JJO has become an international interdisciplinary forum for the publication of basic science and clinical research papers.